ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients ...

The FDA has introduced ELSA, a groundbreaking AI tool designed to expedite the review process for drugs and medical devices.

AI-driven Clairity Breast platform, now FDA-approved, predicts five-year breast cancer risk from mammograms, enhancing early ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

Bayer said it received approval from the Food and Drug Administration for its drug Nubeqa, which treats patients with a certain type of prostate cancer.

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

The Food and Drug Administration (FDA) just green-lit a new Covid vaccine from Moderna, the company said in a press release ...

The FDA rejected Stealth BioTherapeutics’ latest bid to market its proposed treatment for an ultra-rare genetic condition, ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...